{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:20Z","timestamp":1740106940459,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00277-020-04220-1","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T05:25:57Z","timestamp":1597901157000},"page":"2367-2375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy"],"prefix":"10.1007","volume":"99","author":[{"given":"Silvia","family":"Chiesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hohaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Falcinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"D\u2019Al\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo Fabrizio","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Manfrida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-0318","authenticated-orcid":false,"given":"Francesco","family":"Beghella Bartoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Colosimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Aristei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"4220_CR1","volume-title":"Statistical report: primary brain tumors in the United States, 1992\u20131997","author":"CBTRUS","year":"2000","unstructured":"CBTRUS (2000) Statistical report: primary brain tumors in the United States, 1992\u20131997. Central Brain Tumor Registry of the United States, Chicago"},{"key":"4220_CR2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3109\/10428194.2014.961014","volume":"56","author":"S Milgrom","year":"2015","unstructured":"Milgrom S, Yahalom J (2015) The role of radiation therapy in the management of primary central nervous system. Leuk Lymph 56:1197\u20131204","journal-title":"Leuk Lymph"},{"key":"4220_CR3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008201717089","volume":"8","author":"M Reni","year":"1997","unstructured":"Reni M, Ferreri AJM, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8:227\u2013234","journal-title":"Ann Oncol"},{"key":"4220_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","volume":"23","author":"DF Nelson","year":"1992","unstructured":"Nelson DF, Martz KL, Bonner H (1992) Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9\u201317","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 5","key":"4220_CR5","doi-asserted-by":"crossref","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","volume":"27","author":"U Vitolo","year":"2016","unstructured":"Vitolo U, Seymour F, Martelli M et al (2016) Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v91\u2013v102","journal-title":"Ann Oncol"},{"key":"4220_CR6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2003.99.053","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Batchelor T, Zucca EM (2003) International Collaborative Group Against Primary CNS Lymphomas. J Clin Oncol 21:1649\u20131650","journal-title":"J Clin Oncol"},{"key":"4220_CR7","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520","journal-title":"Lancet"},{"key":"4220_CR8","doi-asserted-by":"crossref","unstructured":"Harder H, Holtel H, Bromberg JE et al (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. (4):544\u2013547","DOI":"10.1212\/WNL.62.4.544"},{"key":"4220_CR9","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","volume":"18","author":"LE Abrey","year":"2000","unstructured":"Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144\u20133150","journal-title":"J Clin Oncol"},{"key":"4220_CR10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Ferreri AJ, Marturano E et al (2015) First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL). A systematic review and individual patient data meta-analysis. Ann Oncol 26:1305\u20131313","journal-title":"Ann Oncol"},{"key":"4220_CR11","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","volume":"20","author":"LM DeAngelis","year":"2002","unstructured":"DeAngelis LM, Seiferheld W, Schold SC et al (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643\u20134648","journal-title":"J Clin Oncol"},{"key":"4220_CR12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.11035","volume":"97","author":"Y Shibamoto","year":"2003","unstructured":"Shibamoto Y, Hayabuchi N, Hiratsuka J et al (2003) Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial brain irradiation. Cancer 97:128\u2013133","journal-title":"Cancer"},{"key":"4220_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahalom","year":"2015","unstructured":"Yahalom J, Illidge T, Specht L et al (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiation Biol Oncol Phys 92:11\u201331","journal-title":"Int J Radiation Biol Oncol Phys"},{"key":"4220_CR14","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","volume":"21","author":"K Hoang-Xuan","year":"2003","unstructured":"Hoang-Xuan K, Taillandier L, Chinot O et al (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726\u20132731","journal-title":"J Clin Oncol"},{"key":"4220_CR15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/neuonc\/noq011","volume":"12","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC, Johnston SK (2010) High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol 12:736\u2013744","journal-title":"Neuro Oncol"},{"key":"4220_CR16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.23670","volume":"113","author":"M Ekenel","year":"2008","unstructured":"Ekenel M, Iwamoto FM, Ben-Porat LS et al (2008) Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 113:1025\u20131031","journal-title":"Cancer"},{"key":"4220_CR17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1200\/JCO.2004.99.259","volume":"22","author":"M Reni","year":"2004","unstructured":"Reni M, Ferreri AJM (2004) Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? J Clin Oncol 22:1165\u20131167 author reply 1167-8","journal-title":"J Clin Oncol"},{"key":"4220_CR18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036\u20131047","journal-title":"Lancet Oncol"},{"key":"4220_CR19","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J et al (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31:3971\u20133979","journal-title":"J Clin Oncol"},{"key":"4220_CR20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"4220_CR21","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.ejca.2004.03.008","volume":"40","author":"M Reni","year":"2004","unstructured":"Reni M, Mason W, Zaja F et al (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer. 40:1682\u20131688","journal-title":"Eur J Cancer."},{"key":"4220_CR22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925\u2013937","journal-title":"Biometrics"},{"key":"4220_CR23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341\u20131346","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4220_CR24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649\u2013655","journal-title":"Am J Clin Oncol."},{"key":"4220_CR25","first-page":"266","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Clin Oncol 21:266\u2013272","journal-title":"Clin Oncol"},{"key":"4220_CR26","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043","journal-title":"J Clin Oncol"},{"key":"4220_CR27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"4220_CR28","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013e227","journal-title":"Lancet Haematol"},{"issue":"11","key":"4220_CR29","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"JM Ferreri","year":"2017","unstructured":"Ferreri JM, Cwynarski K, Pulczynski E (2017 Nov) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based hemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomization of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 4(11):e510\u2013e523","journal-title":"Lancet Haematol."},{"key":"4220_CR30","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574","journal-title":"J Clin Oncol"},{"issue":"24","key":"4220_CR31","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus G, Marks R, Ihorst G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 24(24):3865\u20133870. https:\/\/doi.org\/10.1200\/JCO.2006.06.2117","journal-title":"J Clin Oncol."},{"key":"4220_CR32","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD et al (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730\u20134735","journal-title":"J Clin Oncol"},{"key":"4220_CR33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/10428194.2012.698736","volume":"54","author":"L Nayak","year":"2013","unstructured":"Nayak L, Abrey LE, Drappatz J et al (2013) Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 54:58\u201361","journal-title":"Leuk Lymphoma."},{"key":"4220_CR34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.wneu.2018.06.150","volume":"117","author":"J Zheng","year":"2018","unstructured":"Zheng J, Wang C, Liu F (2018) Stereotactic brachytherapy with Iodine-125 seeds plus temozolomide induced complete and durable remission in a patient with recurrent primary central nervous system lymphoma. World Neurosurg 117:316\u2013320","journal-title":"World Neurosurg"},{"key":"4220_CR35","first-page":"1031","volume":"52","author":"M Murakami","year":"2011","unstructured":"Murakami M, Fujimaki T, Asano S et al (2011) Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma. Med J 52:1031\u20131034","journal-title":"Med J"},{"key":"4220_CR36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-011-0652-z","volume":"106","author":"K Makino","year":"2012","unstructured":"Makino K, Nakamura H, Hide T et al (2012) Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol 106:155\u2013160","journal-title":"J Neurooncol"},{"key":"4220_CR37","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.3324\/haematol.2017.185843","volume":"103","author":"R Birsen","year":"2018","unstructured":"Birsen R, Willems L, Pallud J et al (2018) Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients. Haematologica 103:e296\u2013e299","journal-title":"Haematologica"},{"key":"4220_CR38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3109\/10428194.2014.889823","volume":"55","author":"XX Wang","year":"2014","unstructured":"Wang XX, Huang HQ, Bai B et al (2014) Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience. Leuk Lymphoma 55:2497\u20132501","journal-title":"Leuk Lymphoma"},{"key":"4220_CR39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12032-013-0690-9","volume":"30","author":"M Salamoon","year":"2013","unstructured":"Salamoon M, Hussein T, Kenj M et al (2013) High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL). Med Oncol 30:690","journal-title":"Med Oncol"},{"key":"4220_CR40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4103\/0028-3886.115065","volume":"61","author":"Y Wang","year":"2013","unstructured":"Wang Y, Liu B, Xu D et al (2013) Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma. Neurol India 61:260\u2013264","journal-title":"Neurol India"},{"key":"4220_CR41","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","volume":"34","author":"J Glass","year":"2016","unstructured":"Glass J, Won M, Schultz CJ et al (2016) Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227. J Clin Oncol 34:1620\u20131625","journal-title":"J Clin Oncol"},{"key":"4220_CR42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-007-9397-0","volume":"85","author":"AM Omuro","year":"2007","unstructured":"Omuro AM, Taillandier L, Chinot O et al (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85:207\u2013211","journal-title":"J Neurooncol"},{"issue":"Suppl 15","key":"4220_CR43","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1200\/jco.2013.31.15_suppl.2032","volume":"31","author":"AM Omuro","year":"2013","unstructured":"Omuro AM, Chinot OL, Taillandier L et al (2013) Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: an Anocef and Goelams Intergroup study. J Clin Oncol 31(Suppl 15):2032","journal-title":"J Clin Oncol"},{"key":"4220_CR44","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L et al (2015) Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2:e251\u2013e259","journal-title":"Lancet Haematol"},{"key":"4220_CR45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3324\/haematol.2014.108472","volume":"100","author":"EJ Pulczynski","year":"2015","unstructured":"Pulczynski EJ, Kuittinen O, Erlanson M et al (2015) Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica 100:534\u2013540","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04220-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:40:43Z","timestamp":1629416443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04220-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4220"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04220-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"13 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest regarding the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}